McKesson/$MCK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About McKesson

McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Ticker

$MCK
Sector

Primary listing

NYSE

Employees

44,000

McKesson Metrics

BasicAdvanced
$92B
29.58
$24.95
0.51
$2.95
0.44%

What the Analysts think about McKesson

Analyst ratings (Buy, Hold, Sell) for McKesson stock.

Bulls say / Bears say

McKesson raised its fiscal 2026 profit forecast and beat Wall Street revenue and EPS estimates in Q1, reporting $97.83 billion in revenue (consensus $96.08 billion) and adjusted EPS of $8.26 (consensus $8.15), driven by robust demand for specialty medicines (Reuters).
The company lifted its full-year fiscal 2026 adjusted EPS guidance range to $38.05–$38.55, up from $37.10–$37.90, citing strategic emphasis on high-margin oncology and multispecialty segments and raising long-term earnings growth targets to 13%–16% (Reuters).
McKesson’s recent acquisitions have strengthened its specialty and oncology distribution platform, contributing to the segment’s growth and supporting profitability recovery (Reuters).
A June 12, 2025 remittitur in the Baltimore opioid litigation reduced McKesson’s liability to $37 million, but the case remains active and could result in additional damages or a retrial if the city seeks further appeals (SEC 10-Q filing).
McKesson operates with razor-thin profit margins of approximately 1%, leaving its earnings highly sensitive to inflationary cost pressures, reimbursement rate changes, or supply chain disruptions (Barron's).
Trading at around 19 times forward earnings—near the upper end of its historical range—McKesson’s valuation offers limited downside protection and is vulnerable to a multiple contraction if specialty growth expectations are not met (Barron's).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

McKesson Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

McKesson Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MCK

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs